Trenton, February 14, 2022 ― “While we await the opportunity to review the actual bills that Governor Murphy proposed today, we look forward to working with the Administration and Legislature to broaden patient access to innovative medicines and therapies to improve patient outcomes and their quality of life. It is critical that this effort includes examining the supply chain when seeking ways to lower costs for patients. As a recent study by the Berkeley Research Group showed, more than 50% of the cost of brand medicines is attributable to numerous middlemen in the supply chain, including Pharmacy Benefit Managers (PBMs) who are not passing through to patients the manufacturer rebates they receive.”
Menu